Fig. 2
Carbenoxolone (CBX) reduces human AML cell proliferation. a CBX reduces KG1a cell proliferation in a dose- and time-dependent manner. A 50% decrease was observed after exposure to 150 µM of CBX for 48 h. The kinetics of CBX effect on the growth inhibition of KG1a cells, seeded at 2 × 105 cells/mL, was estimated by trypan bleu exclusion assay (n = 5). b CBX exposure for 48 h significantly reduced leukemic cell growth of different AML cell lines (HL-60, KG1a, Molm-13, THP-1, KG-1, and MV4-11) with an IC50 ranging between 100 and 150 µM. AML cell proliferation was tested by MTT assay (n = 5). c CBX (150 µM, 48 h) reduced AML cell lines growth by at least 50%. Cell growth inhibition was determined by counting viable cells using trypan blue exclusion assay (n = 12). d CBX (150 µM, 48 h) reduced primary AML cell growth (n = 5). The number of viable cells after CBX exposure was expressed relatively to untreated cells. Results are expressed as mean ± SEM. *P < 0.05; ***P < 0.001
